Neutralizing antibodies can block infection, clear pathogens, and are essential to provide
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …

Antibody-dependent enhancement (ADE) of disease is a general concern for the
development of vaccines and antibody therapies because the mechanisms that underlie …

Severe COVID-19 is characterized by persistent lung inflammation, inflammatory cytokine
production, viral RNA and a sustained interferon (IFN) response, all of which are …

Feedback inhibition of humoral immunity by antibodies was first documented in 1909.
Subsequent studies showed that, depending on the context, antibodies can enhance or …

ABSTRACT VIR-7831 and VIR-7832 are dual action monoclonal antibodies (mAbs)
targeting the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS …

We examined antibody and memory B cell responses longitudinally for∼ 9–10 months after
primary 2-dose SARS-CoV-2 mRNA vaccination and 3 months after a 3rd dose. Antibody …

Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …

Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infections
and hospitalization in infants under 1 year of age and there is currently no market-approved …

Functional cure of chronic hepatitis B (CHB)—or hepatitis B surface antigen (HBsAg) loss
after 24 weeks off therapy—is now the goal of treatment, but is rarely achieved with current …

Neutralizing antibodies (nAbs) are being increasingly used as passive antiviral reagents in
prophylactic and therapeutic modalities and to guide viral vaccine design. In vivo, nAbs can …